Five years ago, a leading scientific journal laid out the significant potential for collaboration across Parkinson's disease studies such as The Michael J. Fox Foundation (MJFF)'s Parkinson's Progression Markers Initiative and the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarker Program.
This month the same journal, The Lancet Neurology, reports that a new such collaboration -- the Accelerating Medicines Partnership Parkinson's disease (AMP PD) program -- is the "most ambitious initiative so far to find a cure for Parkinson's disease."
The $24-million AMP PD program is led by the Foundation for the National Institutes of Health (NIH) with partners NINDS (part of the NIH), MJFF and five life science companies. AMP PD will use data and samples collected through the Parkinson's Progression Markers Initiative, the Parkinson's Disease Biomarker Program and other studies to learn more about the molecular changes associated with Parkinson's disease.
In an editorial released online ahead of its April 2018 issue, the journal editors write, "Bringing together the collective capabilities and resources across public and private sectors offers the best opportunity to identify and address challenges in early-stage drug development and thus the best opportunity for finding a cure."
PPMI is recruiting people who may carry a genetic risk factor for Parkinson's disease. Take a short survey to see if you may be eligible for genetic testing and counseling at no cost.